Reason for request
Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient. |
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
uT75qM9gx0S3R8WR
